Turn Biotechnologies, Inc. announced that it has received an oversubscribed round of funding on April 12, 2022. The transaction included participation from Astellas Venture Management LLC, Daewoong pharmaceutical Co.,Ltd, Hanall Biopharma Co.,Ltd and other venture capital firms.